Quizartinib is an effective therapy for patients with FLT3-ITD acute myeloid leukemia (AML)
by continuing to inhibit the activity of FLT3 gene, leading to apoptosis of tumor cells. Multiple …

Acute myeloid leukemia (AML) is a heterogeneous disease and remains a therapeutic
challenge. Cytogenetics is a well-established prognostic factor. Recent discovery of …

Introduction. Up to 30% of patients with acute myeloid leukemia (AML) have a mutation in
the FLT3 receptor. Molecular targets have acquired a significant interest in the treatment of …

FLT3/ITD acute myeloid leukemia is a poor prognosis disease driven by a constitutively
activated receptor tyrosine kinase, making it an obvious target for drug development. The …

Acute myeloid leukemia (AML) is a clonal hematologic neoplasm characterized by rapid,
uncontrolled cell growth of immature myeloid cells (blasts). There are numerous genetic …

Introduction: Approximately one-third of the patients with acute myeloid leukemia (AML)
harbor internal tandem duplication (ITD) in the gene encoding FMS-like tyrosine kinase 3 …

Background: FLT3-ITD mutation in acute myeloid leukemia (AML) is associated with early
relapse and poor survival. Quizartinib inhibits FLT3 kinase activity potently and selectively …

Acute myeloid leukemia remains associated with poor outcomes despite advances in our
understanding of the complicated molecular events driving leukemogenesis and malignant …

Novel therapies have potential to improve outcomes in patients with acute myeloid leukemia
(AML) harboring FLT3‐ITD mutations that have high risk of relapse and poor survival …

Introduction: The prognosis of patients with a FLT3-ITD mutation in acute myeloid leukemia
(AML) is worse than FLT3 wild type patients, with increased early relapse including after …